Expanding Global Presence SOMAÍ’s strategic partnerships and recent acquisitions, including collaborations with Sherbinskis and Releaf Dispensary in key European markets, highlight growth opportunities in the medical cannabis sector across Europe and beyond. This expansion provides potential avenues to introduce new product lines or international distribution services.

Innovative Product Lineup The launch of EU-GMP full-spectrum extracts formulated from single-strain full-bud flower demonstrates a focus on pharmaceutical-grade quality, making SOMAÍ well-positioned to meet the demands of high-grade medicinal cannabis markets. Opportunities exist to upsell or develop complementary products tailored to healthcare providers and pharmacies.

Horizontal Market Outreach SOMAÍ’s diverse distribution agreements with wholesalers like Canymed GmbH and collaborations with clinics indicate a strong presence in medical cannabis supply chains. Sales efforts can target healthcare institutions, pharmacies, and clinics looking to expand their cannabis-based treatment options.

Operational Credentials With a state-of-the-art manufacturing facility and indoor cultivation in Portugal, combined with EU-GMP certification, SOMAÍ has the operational credentials to assure quality and consistency. This creates opportunities to attract large-scale healthcare buyers seeking reliable, compliant cannabis products.

Financial and Investment Potential Backed by $10 million in funding and generating revenue between $1 million and $10 million, SOMAÍ shows strong growth potential. Business development efforts can focus on strategic partnerships or investment opportunities to scale distribution, research, and new market entry in the global cannabis industry.